# Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients

> **NCT03067350** · — · COMPLETED · sponsor: **University Hospital, Grenoble** · enrollment: 47 (actual)

## Conditions studied

- Invasive Aspergillosis
- Haematological Cancer Patients
- Voriconazole

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03067350
- **Lead sponsor:** University Hospital, Grenoble
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2019-01
- **Final completion:** 2019-01
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2019-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03067350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03067350, "Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03067350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*